ClinicalTrials.gg
RecruitingNCT06372626Updated Jun 14, 2024

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

A Phase 1/2 interventional study of ZG005 and Etoposide in Neuroendocrine Carcinoma, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Carcinoma, Neuroendocrine with a site in China — 26 open to participants now, 27 under way, 4 of them phase 3. Carcinoma, Neuroendocrine · China.

Planned enrollment
14th of 32
93 · median 80
Started
2024
with 4 others
Phase 1/2
9 of 39
8 open now
Primary completion
2026-07
later than 3 of 26 live
Registered
22nd of 39
by date
Lead sponsor
7 of 39
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, this one is the 14th largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2024, is one of 9 in phase 1/2, reaches primary completion later than 3 of the 26 other live ones, and was the 22nd registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

26 of the 39 studies in Carcinoma, Neuroendocrine with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Carcinoma, Neuroendocrine with a site in China, or all of them as a file.
02

Study summary

The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.

03

Conditions studied

  • Neuroendocrine Carcinoma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand the study and voluntarily sign the form.
  • Male or female 18-70 years of age.
  • (ECOG) Performance Status of 0-1.
  • confirmed recurrent or neuroendocrine carcinoma
  • ≥ 3 months.

Exclusion criteria

Exclusion Criteria:

  • Medical history, computed tomography or magnetic resonance imaging results indicate that existence of the central nervous system ;
  • Any other within 5 years.
  • participants were deemed unsuitable for participating in the study by the investigator for any reasons.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Dose-escalation study of ZG005 in combination with Etoposide and Cisplatin.

    Biological: ZG005 · Drug: Etoposide · Drug: Cisplatin

  • Experimental
    Part 2: Dose Expansion

    Group A: ZG005 in combination with Etoposide and Cisplatin; Group B: Placebo in combination with Etoposide and Cisplatin.

    Biological: ZG005 · Drug: Etoposide · Drug: Cisplatin · Drug: Placebo

Interventions

  • BiologicalZG005

    ZG005 for dose escalations are set as 10mg/kg, 20mg/kg, and the other doses after discussion. intravenous infusion, once every 3 weeks. ZG005 for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.

  • IV infusion

  • IV infusion

  • DrugPlacebo

    0.9% Sodium Chloride Injection

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    Time frame: Up to 2 years

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of the participants in the analysis population who have a Complete Response or a Partial Response. The ORR per RECIST 1.1 as assessed by Investigator is presented

    Time frame: Up to 2 years

  3. Adverse Event (AE)

    Number of participants with adverse events that are related to treatment

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jul 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 18, 2024
StartActual
May 30, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Aug 2026
Last update
Jun 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06372626
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
May 30, 2024
Primary completion
Jul 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jun 14, 2024

Study contacts

Cheng Wei
Contact
weic@zelgen.com
+8651257309965
Jason Wu
study chair · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilvanstomig

Start the discussion